1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
Abstract
:1. Introduction
2. Methods
2.1. Radiotherapy Procedures
2.2. Toxicity and Quality of Life Assessment
- –
- International Prostatic Symptoms Score (IPSS)
- –
- EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EORTC QLQ-PR25
- –
- Expanded Prostate Cancer Index Composite-26 (EPIC-26)
- –
- International Consultation on Incontinence Questionnaire—Short Form (ICIQ-SF)
- –
- International Index of Erectile Function—5 (IIEF-5)
2.3. Statistical Analysis
3. Results
3.1. Acute Toxicity
3.2. Late Toxicity
3.3. PROMs Assessment
- –
- IPSS: Median IPSS scores were 4.7 at baseline, 9.7 at the end of MR-guided adaptive SBRT and 6.3 at the first follow-up. We reported a significant increase in the IPSS score at the end of radiation treatment (p: 0.001), with a return to similar baseline values by the second follow-up (p: 0.81).
- –
- EORTC-QLQ-PR25: Only the urinary symptoms, incontinence aid and bowel symptoms were affected to a statistically significant magnitude after treatment and at the first follow-up, with a return to baseline values at the second follow-up assessment.
- –
- ICIQ-SF: a significant variation was only recorded at the end of treatment time, with a return to baseline values at the first follow-up
- –
- IIEF-5: A statistically significant score reduction was registered at the post-RT time and at the first follow-up, with a return to baseline conditions at the second follow-up time.
- –
- EPIC-26: Urinary symptom items were significantly affected after the end of treatment and at the first follow-up evaluation. The sexual functioning domain was significantly affected at each assessment time, up to the 12 months evaluation.
- –
- EORTC-QLQ-C30: Financial difficulties, pain, insomnia and physical and role functioning were affected at the initial post-SBRT assessments with a return to baseline values by the second follow-up; interestingly, global health status, and emotional and social functioning domains reported improved scores of a statistically significant magnitude compared to baseline values at the third follow-up assessment.
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- European Comission Estimates of Cancer Incidence and Mortality in 2020, for All Countries. 2020. Available online: https://ecis.jrc.ec.europa.eu/explorer.php?$0-1$1-All$2-All$4-1,2$3-0$6-0,85$5-2004,2010$7-2$CRatesByRegistry$X0_10-ASR_EU_NEW (accessed on 16 June 2022).
- Hamdy, F.C.; Donovan, J.L.; Lane, J.A.; Mason, M.; Metcalfe, C.; Holding, P.; Davis, M.; Peters, T.J.; Turner, E.L.; Martin, R.M.; et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N. Engl. J. Med. 2016, 375, 1415–1424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Catton, C.N.; Lukka, H.; Gu, C.S.; Martin, J.M.; Supiot, S.; Chung, P.W.M.; Bauman, G.S.; Bahary, J.P.; Ahmed, S.; Cheung, P.; et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J. Clin. Oncol. 2017, 35, 1884–1890. [Google Scholar] [CrossRef] [PubMed]
- De Vries, K.C.; Wortel, R.C.; Oomen-de Hoop, E.; Heemsbergen, W.D.; Pos, F.J.; Incrocci, L. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes from the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. Int. J. Radiat. Oncol. Biol. Phys. 2020, 106, 108–115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dearnaley, D.; Syndikus, I.; Mossop, H.; Khoo, V.; Birtle, A.; Bloomfield, D.; Graham, J.; Kirkbride, P.; Logue, J.; Malik, Z.; et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016, 17, 1047–1060, Erratum in Lancet Oncol. 2016, 17, e321. [Google Scholar] [CrossRef] [Green Version]
- NCCN Guidelines Version 3.2022—Prostate Cancer. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed on 16 June 2022).
- Brand, D.H.; Tree, A.C.; Ostler, P.; van der Voet, H.; Loblaw, A.; Chu, W.; Ford, D.; Tolan, S.; Jain, S.; Martin, A.; et al. PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019, 20, 1531–1543. [Google Scholar] [CrossRef]
- Widmark, A.; Gunnlaugsson, A.; Beckman, L.; Thellenberg-Karlsson, C.; Hoyer, M.; Lagerlund, M.; Kindblom, J.; Ginman, C.; Johansson, B.; Björnlinger, K.; et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019, 394, 385–395. [Google Scholar] [CrossRef]
- Tocco, B.R.; Kishan, A.U.; Ma, T.M.; Kerkmeijer, L.G.W.; Tree, A.C. MR-Guided Radiotherapy for Prostate Cancer. Front. Oncol. 2020, 10, 616291. [Google Scholar] [CrossRef]
- Corradini, S.; Alongi, F.; Andratschke, N.; Belka, C.; Boldrini, L.; Cellini, F.; Debus, J.; Guckenberger, M.; Hörner-Rieber, J.; Lagerwaard, F.J.; et al. MR-guidance in clinical reality: Current treatment challenges and future perspectives. Radiat. Oncol. 2019, 14, 92. [Google Scholar] [CrossRef] [Green Version]
- Pathmanathan, A.U.; Schmidt, M.A.; Brand, D.H.; Kousi, E.; van As, N.J.; Tree, A.C. Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI. J. Appl. Clin. Med. Phys. 2019, 20, 27–36. [Google Scholar] [CrossRef] [Green Version]
- Corradini, S.; Alongi, F.; Andratschke, N.; Azria, D.; Bohoudi, O.; Boldrini, L.; Bruynzeel, A.; Hörner-Rieber, J.; Jürgenliemk-Schulz, I.; Lagerwaard, F.; et al. ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiother. Oncol. 2021, 159, 146–154. [Google Scholar] [CrossRef]
- Ma, T.M.; Lamb, J.M.; Casado, M.; Wang, X.; Basehart, T.V.; Yang, Y.; Low, D.; Sheng, K.; Agazaryan, N.; Nickols, N.G.; et al. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): A phase III randomized trial. BMC Cancer 2021, 21, 538. [Google Scholar] [CrossRef] [PubMed]
- Cuccia, F.; Corradini, S.; Mazzola, R.; Spiazzi, L.; Rigo, M.; Bonù, M.L.; Ruggieri, R.; Buglione di Monale EBastia, M.; Magrini, S.M.; Alongi, F. MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. Cancers 2021, 13, 1791. [Google Scholar] [CrossRef] [PubMed]
- Bruynzeel, A.M.E.; Tetar, S.U.; Oei, S.S.; Senan, S.; Haasbeek, C.J.A.; Spoelstra, F.O.B.; Piet, A.H.M.; Meijnen, P.; Bakker van der Jagt, M.A.B.; Fraikin, T.; et al. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Int. J. Radiat. Oncol. Biol. Phys. 2019, 105, 1086–1094. [Google Scholar] [CrossRef] [PubMed]
- Tetar, S.U.; Bruynzeel, A.M.E.; Oei, S.S.; Senan, S.; Fraikin, T.; Slotman, B.J.; Moorselaar, R.J.A.V.; Lagerwaard, F.J. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur. Urol. Oncol. 2021, 4, 628–634. [Google Scholar] [CrossRef] [PubMed]
- Alongi, F.; Rigo, M.; Figlia, V.; Cuccia, F.; Giaj-Levra, N.; Nicosia, L.; Ricchetti, F.; Sicignano, G.; De Simone, A.; Naccarato, S.; et al. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: Feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat. Oncol. 2020, 15, 69. [Google Scholar] [CrossRef]
- Prostate Radiotherapy Integrated with Simultaneous MRI (The PRISM Study) (PRISM). Available online: https://clinicaltrials.gov/ct2/show/NCT03658525 (accessed on 16 June 2022).
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (MOMENTUM). Available online: https://clinicaltrials.gov/ct2/show/NCT04075305 (accessed on 16 June 2022).
- Brenner, D.J.; Martinez, A.A.; Edmundson, G.K.; Mitchell, C.; Thames, H.D.; Armour, E.P. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 6–13. [Google Scholar] [CrossRef]
- Ruggieri, R.; Rigo, M.; Naccarato, S.; Gurrera, D.; Figlia, V.; Mazzola, R.; Ricchetti, F.; Nicosia, L.; Giaj-Levra, N.; Cuccia, F.; et al. Adaptive SBRT by 1.5 T MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. Phys. Med. 2020, 80, 34–41. [Google Scholar] [CrossRef]
- Naccarato, S.; Rigo, M.; Pellegrini, R.; Voet, P.; Akhiat, H.; Gurrera, D.; De Simone, A.; Sicignano, G.; Mazzola, R.; Figlia, V.; et al. Automated Planning for Prostate Stereotactic Body Radiation Therapy on the 1.5 T MR-Linac. Adv. Radiat. Oncol. 2022, 7, 100865. [Google Scholar] [CrossRef]
- Ugurluer, G.; Atalar, B.; Zoto Mustafayev, T.; Gungor, G.; Aydin, G.; Sengoz, M.; Abacioglu, U.; Tuna, M.B.; Kural, A.R.; Ozyar, E. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: Preliminary results of outcome and toxicity. Br. J. Radiol. 2021, 94, 20200696. [Google Scholar] [CrossRef]
- Alongi, F.; Rigo, M.; Figlia, V.; Cuccia, F.; Giaj-Levra, N.; Nicosia, L.; Ricchetti, F.; Vitale, C.; Sicignano, G.; De Simone, A.; et al. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: Dosimetric analysis and preliminary patient-reported outcomes. Br. J. Radiol. 2021, 94, 20200848. [Google Scholar] [CrossRef]
- Cuccia, F.; Mazzola, R.; Nicosia, L.; Figlia, V.; Giaj-Levra, N.; Ricchetti, F.; Rigo, M.; Vitale, C.; Mantoan, B.; De Simone, A.; et al. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat. Oncol. 2020, 15, 178. [Google Scholar] [CrossRef] [PubMed]
- Magli, A.; Farneti, A.; Faiella, A.; Ferriero, M.; Landoni, V.; Giannarelli, D.; Moretti, E.; de Paula, U.; Gomellini, S.; Sanguineti, G. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, 93–100. [Google Scholar] [CrossRef] [PubMed]
- Kishan, A.U.; Dang, A.; Katz, A.J. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw. Open 2019, 2, e188006. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Value |
---|---|
Age | 71 years (range, 52–84) |
Risk Group | |
Low Risk | 34 |
Intermediate Risk (Favorable/Unfavorable) | 60 (29/31) |
High Risk | 2 |
M1 low-volume | 4 |
RT Schedule | 35 Gy/5 fx (n = 55); 36,25 Gy/5 fx (n = 45) |
Daily vs. Alternate Days | 75/25 |
Hydrogel Spacer (y/n) | 37/63 |
Androgen Deprivation Therapy (y/n) | 32/68 |
ATP vs. ATS | 20/480 |
Treatment Time | 40 min (33–83) |
Genitourinary | G1 | G2 | ||
---|---|---|---|---|
Urinary Tract Pain | 15 | 5 | ||
Urinary Urgency | 11 | - | ||
Urethral Stenosis | 1 | 2 | ||
Gastrointestinal | G1 | G2 | ||
Diarrhea | - | - | ||
Rectal Tenesmus | 5 | 3 | ||
Rectal Proctitis | 4 | 1 | ||
Genitourinary | G1 | G2 | G3 | |
Urinary Tract Pain | 10 | 2 | - | |
Urinary Stenosis | 3 | 1 | 1 | |
Hematuria | - | - | ||
Gastrointestinal | G1 | G2 | G3 | |
Diarrhea | - | - | - | |
Rectal Tenesmus | 2 | - | ||
Rectal Bleeding | - | - | 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alongi, F.; Rigo, M.; Figlia, V.; Nicosia, L.; Mazzola, R.; Giaj Levra, N.; Ricchetti, F.; Trapani, G.; Attinà, G.; Vitale, C.; et al. 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients. J. Pers. Med. 2022, 12, 1982. https://doi.org/10.3390/jpm12121982
Alongi F, Rigo M, Figlia V, Nicosia L, Mazzola R, Giaj Levra N, Ricchetti F, Trapani G, Attinà G, Vitale C, et al. 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients. Journal of Personalized Medicine. 2022; 12(12):1982. https://doi.org/10.3390/jpm12121982
Chicago/Turabian StyleAlongi, Filippo, Michele Rigo, Vanessa Figlia, Luca Nicosia, Rosario Mazzola, Niccolò Giaj Levra, Francesco Ricchetti, Giovanna Trapani, Giorgio Attinà, Claudio Vitale, and et al. 2022. "1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients" Journal of Personalized Medicine 12, no. 12: 1982. https://doi.org/10.3390/jpm12121982